Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q3 2021 · 10-Q
Revenue$233.00K$233.00Kno prior Q3 2020 on file Net Income-$6.42M-$6.42MN/M vs Q3 2020 EPS Diluted-$0.30-$0.30N/M vs Q3 2020 Operating Income-$6,469,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,656,000— Margins · derivedOperating margin-2776.4%
Net margin-2756.7%
ended Sep 30, 2021 · filed Nov 12, 2021 · 43 d after period end